Multiple myeloma: A paradigm for translation of the cancer stem cell hypothesis

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 116-120

  Agarwal, Jasmin Roya ^a   Matsui, William ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer stem cells; Developmental pathways; Hedgehog; Multiple myeloma

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; CYCLOPAMINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GDC 0449; GRN 163 L; INTERFERON; INTERLEUKIN 6; LENALIDOMIDE; NOTCH RECEPTOR; PROTEIN INHIBITOR; RITUXIMAB; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; SYNDECAN 1; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL HETEROGENEITY; CELL POPULATION; CELL RENEWAL; CELL TRANSFORMATION; CLONOGENIC ASSAY; CYTOTOXICITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HYPOTHESIS; MEDULLOBLASTOMA; MULTIPLE MYELOMA; MUTATION; NONHUMAN; NONOBESE DIABETIC MOUSE; PLASMA CELL; PLASMACYTOMA; REVIEW; SCID MOUSE; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 77950826827     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010790909344     Document Type: Review

References (66)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. Cancer statistics, 2009. CA: CA Cancer J. Clin., 2009, 59(4), 225-249.
2. Kyle, R.A.; Rajkumar, S.V. Multiple myeloma. N. Engl. J. Med., 2004, 351(18), 1860-1873.
3. Oken, M.M.; Harrington, D.P.; Abramson, N.; Kyle, R.A.; Knospe, W.; Glick, J.H. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group study E2479. Cancer, 1997, 79(8), 1561-1567.
4. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J. Clin. Oncol., 1998, 16(12), 3832-3842.
5. Koreth, J.; Cutler, C.; Djulbegovic, B.; Behl, R.; Schlossman, R.; Munshi, N.; Richardson, P.; Anderson, K.; Soiffer, R.; Alyea, E. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol. Blood Marrow Transplant., 2007, 13(2), 183-196.
6. Raab, M.S.; Podar, K.; Breitkreutz, I.; Richardson, P.G.; Anderson, K.C. Multiple myeloma. Lancet, 2009, 374(9686), 324-339.
7. Bensinger, W.I. Allogeneic hematopoietic cell transplantation for multiple myeloma. Biomed. Pharmacother., 2002, 56(3), 133-138.
8. Maloney, D.G.; Molina, A.J.; Sahebi, F.; Stockerl-Goldstein, K.E.; Sandmaier, B.M.; Bensinger, W.; Storer, B.; Hegenbart, U.; Somlo, G.; Chauncey, T.; Bruno, B.; Appelbaum, F.R.; Blume, K.G.; Forman, S.J.; Mcsweeney, P.; Storb, R. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 2003, 102(9), 3447-3454.
9. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 1999, 341(21), 1565-1571.
10. Richardson, P.G.; Schlossman, R.L.; Weller, E.; Hideshima, T.; Mitsiades, C.; Davies, F.; Leblanc, R.; Catley, L.P.; Doss, D.; Kelly, K.; Mckenney, M.; Mechlowicz, J.; Freeman, A.; Deocampo, R.; Rich, R.; Ryoo, J.J.; Chauhan, D.; Balinski, K.; Zeldis, J.; Anderson, K.C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 2002, 100(9), 3063-3067.
11. Richardson, P.G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S.V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R.Z.; Kuter, D.; Limentani, S.A.; Lee, S.; Hideshima, T.; Esseltine, D.L.; Kauffman, M.; Adams, J.; Schenkein, D.P.; Anderson, K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med., 2003, 348(26), 2609-2617.
12. Kumar, S.K.; Rajkumar, S.V.; Dispenzieri, A.; Lacy, M.Q.; Hayman, S.R.; Buadi, F.K.; Zeldenrust, S.R.; Dingli, D.; Russell, S.J.; Lust, J.A.; Greipp, P.R.; Kyle, R.A.; Gertz, M.A. Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008, 111(5), 2516-2520.
13. Bergsagel, D.E.; Valeriote, F.A. Growth characteristics of a mouse plasma cell tumor. Cancer Res., 1968, 28(11), 2187-2196.
14. Park, C.H.; Bergsagel, D.E.; Mcculloch, E.A. Mouse myeloma tumor stem cells: a primary cell culture assay. J. Natl. Cancer Inst., 1971, 46(2), 411-422.
15. Drewinko, B.; Alexanian, R.; Boyer, H.; Barlogie, B.; Rubinow, S.I. The growth fraction of human myeloma cells. Blood, 1981, 57(2), 333-338.
16. Hamburger, A.; Salmon, S.E. Primary bioassay of human myeloma stem cells. J. Clin. Invest., 1977, 60(4), 846-854.
17. Hamburger, A.W.; Kim, M.B.; Salmon, S.E. The nature of cells generating human myeloma colonies in vitro. J. Cell Physiol., 1979, 98(2), 371-376.
18. Wijdenes, J.; Vooijs, W.C.; Clement, C.; Post, J.; Morard, F.; Vita, N.; Laurent, P.; Sun, R.X.; Klein, B.; Dore, J.M. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br. J. Haematol., 1996, 94(2), 318-323.
19. Chilosi, M.; Adami, F.; Lestani, M.; Montagna, L.; Cimarosto, L.; Semenzato, G.; Pizzolo, G.; Menestrina, F. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Modern Pathol., 1999, 12(12), 1101-1106.
20. Matsui, W.; Huff, C.A.; Wang, Q.; Malehorn, M.T.; Barber, J.; Tanhehco, Y.; Smith, B.D.; Civin, C.I.; Jones, R.J. Characterization of clonogenic multiple myeloma cells. Blood, 2004, 103(6), 2332-2336.
21. Billadeau, D.; Ahmann, G.; Greipp, P.; Van Ness, B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J. Exp. Med., 1993, 178(3), 1023-1031.
22. Bakkus, M.H.; Heirman, C.; Van Riet, I.; Van Camp, B.; Thielemans, K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood, 1992, 80(9), 2326-2335.
23. Bakkus, M.H.; Van, R.I.; Van Camp, B.; Thielemans, K. Evidence that the clonogenic cell in multiple myeloma originates from a preswitched but somatically mutated B cell. Br. J. Haematol., 1994, 87(1), 68-74.
24. Bergsagel, P.L.; Smith, A.M.; Szczepek, A.; Mant, M.J.; Belch, A.R.; Pilarski, L.M. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood, 1995, 85(2), 436-447.
25. Chen, B.J.; Epstein, J. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood, 1996, 87(5), 1972-1976.
26. Szczepek, A.J.; Seeberger, K.; Wizniak, J.; Mant, M.J.; Belch, A.R.; Pilarski, L.M. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood, 1998, 92(8), 2844-2855.
27. Rasmussen, T. The presence of circulating clonal CD19+ cells in multiple myeloma. Leuk. Lymphoma, 2001, 42(6), 1359-1366.
28. Rasmussen, T.; Lodahl, M.; Hancke, S.; Johnsen, H.E. In multiple myeloma clonotypic CD38-/CD19+/CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk. Lymphoma, 2004, 45(7), 1413-1417.
29. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.C.-C.J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into scid mice. Nature, 1994, 367(6464), 645-648.
30. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
31. Fearon, D.T.; Manders, P.; Wagner, S.D. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science, 2001, 293(5528), 248-250.
32. Crotty, S.; Felgner, P.; Davies, H.; Glidewell, J.; Villarreal, L.; Ahmed, R. Cutting edge: Long-term B cell memory in humans after smallpox vaccination. J. Immunol., 2003, 171(10), 4969-4973.
33. Mcheyzer-Williams, L.J.; Mcheyzer-Williams, M.G. Antigenspecific memory B cell development. Ann. Rev. Immunol., 2005, 23(1), 487-513.
34. Matsui, W.; Wang, Q.; Barber, J.P.; Brennan, S.; Smith, B.D.; Borrello, I.; Mcniece, I.; Lin, L.; Ambinder, R.F.; Peacock, C.; Watkins, D.N.; Huff, C.A.; Jones, R.J. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res., 2008, 68(1), 190-197.
35. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.M.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem cells--perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res., 2006, 66(19), 9339-9344.
36. Goodell, M.A.; Brose, K.; Paradis, G.; Conner, A.S.; Mulligan, R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med., 1996, 183(4), 1797-1806.
37. Jones, R.J.; Barber, J.P.; Vala, M.S.; Collector, M.I.; Kaufmann, S.H.; Ludeman, S.M.; Colvin, O.M.; Hilton, J. Assessment of aldehyde dehydrogenase in viable cells. Blood, 1995, 85(10), 2742-2746.
38. Cheng, T.; Rodrigues, N.; Shen, H.; Yang, Y.; Dombkowski, D.; Sykes, M.; Scadden, D.T. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science, 2000, 287(5459), 1804-1808.
39. Peacock, C.D.; Wang, Q.; Gesell, G.S.; Corcoran-Schwartz, I.M.; Jones, E.; Kim, J.; Devereux, W.L.; Rhodes, J.T.; Huff, C.A.; Beachy, P.A.; Watkins, D.N.; Matsui, W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl. Acad. Sci. USA, 2007, 104(10), 4048-4053.
40. Matsui, W.; Wang, Q.; Vala, M.; Barber, J.P.; Meeker, A.; Tressler, R.; Harley, C.; Huff, C.A.; Smith, B.D.; Jones, R.J. Cancer stem cell targeting in multiple myeloma by GRN163L, a novel and potent telomerase inhibitor. Blood (ASH Annual Meeting Abstracts), 2006, 108(11), 2540.
41. Matsui, W.; Huff, C.A.; Vala, M.; Barber, J.; Smith, B.D.; Jones, R.J. Anti-tumour activity of interferon-alpha in multiple myeloma: Role of interleukin 6 and tumor cell differentiation. Br. J. Haematol., 2003, 121(2), 251-258.
42. Taipale, J.; Beachy, P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature, 2001, 411(6835), 349-354.
43. Ruiz I Altaba, A.; Sanchez, P.; Dahmane, N. Gli and Hedgehog in cancer: tumours, embryos and stem cells. Nat. Rev. Cancer, 2002, 2(5), 361-372.
44. Taipale, J.; Cooper, M.K.; Maiti, T.; Beachy, P.A. Patched acts catalytically to suppress the activity of smoothened. Nature, 2002, 418(6900), 892-897.
45. Duman-Scheel, M.; Weng, L.; Xin, S.; Du, W. Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature, 2002, 417(6886), 299-304.
46. Ruiz I Altaba, A.; Mas, C.; Stecca, B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol., 2007, 17(9), 438-447.
47. Gailani, M.R.; Stahle-Backdahl, M.; Leffell, D.J.; Glynn, M.; Zaphiropoulos, P.G.; Pressman, C.; Unden, A.B.; Dean, M.; Brash, D.E.; Bale, A.E.; Toftgard, R. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat. Genet., 1996, 14(1), 78-81. (Pubitemid 26301550)
48. Raffel, C.; Jenkins, R.B.; Frederick, L.; Hebrink, D.; Alderete, B.; Fults, D.W.; James, C.D. Sporadic medulloblastomas contain PTCH mutations. Cancer Res., 1997, 57(5), 842-845.
49. Berman, D.M.; Karhadkar, S.S.; Maitra, A.; Montes, D.O.; Gerstenblith, M.R.; Briggs, K.; Parker, A.R.; Shimada, Y.; Eshleman, J.R.; Watkins, D.N.; Beachy, P.A. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature, 2003, 425(6960), 846-851.
50. Watkins, D.N.; Berman, D.M.; Burkholder, S.G.; Wang, B.; Beachy, P.A.; Baylin, S.B. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature, 2003, 422(6929), 313-317.
51. Karhadkar, S.S.; Bova, G.S.; Abdallah, N.; Dhara, S.; Gardner, D.; Maitra, A.; Isaacs, J.T.; Berman, D.M.; Beachy, P.A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature, 2004, 431(7009), 707-712.
52. Yauch, R.L.; Gould, S.E.; Scales, S.J.; Tang, T.; Tian, H.; Ahn, C.P.; Marshall, D.; Fu, L.; Januario, T.; Kallop, D.; Nannini-Pepe, M.; Kotkow, K.; Marsters, J.C.; Rubin, L.L.; De Sauvage, F.J. A paracrine requirement for Hedgehog signalling in cancer. Nature, 2008, 455(7211), 406-410.
53. Tian, H.; Callahan, C.A.; Dupree, K.J.; Darbonne, W.C.; Ahn, C.P.; Scales, S.J.; De Sauvage, F.J. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc. Natl. Acad. Sci. USA, 2009, 106(11), 4254-4259.
54. Dierks, C.; Beigi, R.; Guo, G.R.; Zirlik, K.; Stegert, M.R.; Manley, P.; Trussell, C.; Schmitt-Graeff, A.; Landwerlin, K.; Veelken, H.; Warmuth, M. Expansion of bcr-abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell, 2008, 14(3), 238-249.
55. Zhao, C.; Chen, A.; Jamieson, C.H.; Fereshteh, M.; Abrahamsson, A.; Blum, J.; Kwon, H.Y.; Kim, J.; Chute, J.P.; Rizzieri, D.; Munchhof, M.; VanArsdale, T.; Beachy, P.A.; Reya, T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature, 2009, 458(7239), 776-779.
56. Bar, E.E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; Vescovi, A.L.; Dimeco, F.; Olivi, A.; Eberhart, C.G. Cyclopamine-mediated Hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells, 2007, 25(10), 2524-2533.
57. Liu, S.; Dontu, G.; Mantle, I.D.; Patel, S.; Ahn, N.S.; Jackson, K.W.; Suri, P.; Wicha, M.S. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res., 2006, 66(12), 6063-6071.
58. Dierks, C.; Grbic, J.; Zirlik, K.; Beigi, R.; Englund, N.P.; Guo, G.R.; Veelken, H.; Engelhardt, M.; Mertelsmann, R.; Kelleher, J.F.; Schultz, P.; Warmuth, M. Essential role of stromally induced Hedgehog signaling in B-cell malignancies. Nat. Med., 2007, 13(8), 944-951.
59. Von Hoff, D.; Lorusso, P.; Rudin, C.; Reddy, J.; Yauch, R.; Tibes, R.; Weiss, G.; Borad, M.; Hann, C.; Brahmer, J.; Mackey, H.; Lum, B.; Darbonne, W.; Marsters, J.; De Sauvage, F.; Low, J. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med., 2009, 361(12), 1164-1172.
60. Rudin, C.M.; Hann, C.L.; Laterra, J.; Yauch, R.L.; Callahan, C.A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S.E.; Coleman, B.; Lorusso, P.M.; Von Hoff, D.D.; De Sauvage, F.J.; Low, J.A. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med., 2009, 361(12), 1173-1178.
61. Hyman, J.M.; Firestone, A.J.; Heine, V.M.; Zhao, Y.; Ocasio, C.A.; Han, K.; Sun, M.; Rack, P.G.; Sinha, S.; Wu, J.J.; Solow-Cordero, D.E.; Jiang, J.; Rowitch, D.H.; Chen, J.K. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc. Natl. Acad. Sci. USA, 2009, 106(33), 14132-14137.
62. Lauth, M.; Bergström, A.; Shimokawa, T.; Toftgård, R. Inhibition of Gli-mediated transcription and tumor cell growth by smallmolecule antagonists. Proc. Natl. Acad. Sci. USA, 2007, 104(20), 8455-8460.
63. Jones, R.J.; Matsui, W.H.; Smith, B.D. Cancer stem cells: are we missing the target? J. Natl. Cancer Inst., 2004, 96(8), 583-585.
64. Palumbo, A.; Bringhen, S.; Caravita, T.; Merla, E.; Capparella, V.; Callea, V.; Cangialosi, C.; Grasso, M.; Rossini, F.; Galli, M.; Catalano, L.; Zamagni, E.; Petrucci, M.T.; De Stefano, V.; Ceccarelli, M.; Ambrosini, M.T.; Avonto, I.; Falco, P.; Ciccone, G.; Liberati, A.M.; Musto, P.; Boccadoro, M.; Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, 2006, 367(9513), 825-831.
65. Miguel, S.J.F.; Schlag, R.; Khuageva, N.K.; Dimopoulos, M.A.; Shpilberg, O.; Kropff, M.; Spicka, I.; Petrucci, M.T.; Palumbo, A.; Samoilova, O.S.; Dmoszynska, A; Abdulkadyrov, K.M.; Schots, R.; Jiang, B.; Mateos, M.V.; Anderson, K.C.; Esseltine, D.L.; Liu, K.; Cakana, A.; van de Velde, H.; Richardson, P.G.; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med., 2008, 359(9), 906-917.
66. Huff, C.A.; Matsui, W.; Smith, B.D.; Jones, R.J. The paradox of response and survival in cancer therapeutics. Blood, 2006, 107(2), 431-434.